Literature DB >> 15682310

Nicotinic-serotonergic drug interactions and attentional performance in rats.

Amir H Rezvani1, D Patrick Caldwell, Edward D Levin.   

Abstract

RATIONALE: Both central serotonergic and nicotinic systems play important roles in a variety of neurobehavioral functions; however, the interactions of these two systems have not been fully characterized. The current study served to determine the impact of a relatively selective 5-HT2A receptor antagonist, ketanserin, on attentional function in rats and the interactions of ketanserin with nicotine administration.
METHODS: A standard operant visual signal detection task was used to assess sustained attention. In expt 1, adult female Sprague-Dawley rats (n = 39) were injected subcutaneously (SC) with a dose range of ketanserin (0, 0.25, 0.5 and 1 mg/kg). In expt 2, the interactions of acute ketanserin (0, 1 and 2 mg/kg, SC) and acute nicotine (0, 25 and 50 microg/kg, SC) were assessed. In expt 3, the interaction of acute ketanserin (0, 1 and 2 mg/kg, SC) and chronic nicotine (5 mg/kg per day, SC for 4 weeks via osmotic pump) was characterized. Using an operant visual signal detection task, three possible outcomes (dependent variables) were measured in each trial: percent hit, percent correct rejection, and response omissions.
RESULTS: Ketanserin, when given alone, did not have a significant effect on either percent hit or percent correct rejection. Acute administration of 25 microg/kg nicotine significantly improved percent hit (i.e. improvement in choice accuracy), an effect that was reversed by acute administration of 1 mg/kg ketanserin. Chronic nicotine infusion for 28 consecutive days significantly increased percent correct rejection (i.e. improvement in choice accuracy) without development of tolerance, an effect which was reversed by an acute dose of 2 mg/kg ketanserin.
CONCLUSIONS: These data suggest a functional interaction between nicotine and 5-HT2A receptor antagonist ketanserin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15682310     DOI: 10.1007/s00213-004-2060-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  46 in total

1.  The physiological role of 5-HT2A receptors in working memory.

Authors:  Graham V Williams; Srinivas G Rao; Patricia S Goldman-Rakic
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

2.  Transdermal nicotine effects on attention.

Authors:  E D Levin; C K Conners; D Silva; S C Hinton; W H Meck; J March; J E Rose
Journal:  Psychopharmacology (Berl)       Date:  1998-11       Impact factor: 4.530

3.  The nicotinic receptor agonists (-)-nicotine and isoarecolone differ in their effects on dopamine release in the nucleus accumbens.

Authors:  N R Mirza; Q Pei; I P Stolerman; T S Zetterström
Journal:  Eur J Pharmacol       Date:  1996-01-11       Impact factor: 4.432

4.  Differential effects of three 5-HT receptor antagonists on the performance of rats in attentional and working memory tasks.

Authors:  S Ruotsalainen; J Sirviö; P Jäkälä; T Puumala; E MacDonald; P Riekkinen
Journal:  Eur Neuropsychopharmacol       Date:  1997-05       Impact factor: 4.600

5.  The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus.

Authors:  K Antoniou; S Bekris; M Saranti; P Stathis; M Rimikis; Z Papadopoulou-Daifoti
Journal:  Eur Neuropsychopharmacol       Date:  2000-09       Impact factor: 4.600

6.  Nicotine enhances sustained attention in the rat under specific task conditions.

Authors:  N R Mirza; I P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  1998-08       Impact factor: 4.530

7.  Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron.

Authors:  J L Muir; B J Everitt; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

8.  Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats.

Authors:  J Turchi; L A Holley; M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

9.  Nicotine administration to rats: methodological considerations.

Authors:  L C Murrin; J R Ferrer; W Y Zeng; N J Haley
Journal:  Life Sci       Date:  1987-04-27       Impact factor: 5.037

10.  Alzheimer disease, attention, and the cholinergic system.

Authors:  A D Lawrence; B J Sahakian
Journal:  Alzheimer Dis Assoc Disord       Date:  1995       Impact factor: 2.703

View more
  16 in total

1.  Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats.

Authors:  Amir H Rezvani; Marty Cauley; Hannah Sexton; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

2.  Strain dependency of the effects of nicotine and mecamylamine in a rat model of attention.

Authors:  Britta Hahn; Katelyn E Riegger; Greg I Elmer
Journal:  Psychopharmacology (Berl)       Date:  2016-02-15       Impact factor: 4.530

3.  Attention-enhancing effects of propranolol and synergistic effects with nicotine.

Authors:  Britta Hahn; Cory K Olmstead; Marie B Yuille; Joshua J Chiappelli; Ashleigh K Wells
Journal:  Cogn Affect Behav Neurosci       Date:  2020-06       Impact factor: 3.282

4.  The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition.

Authors:  Shahrdad Lotfipour; Monica M Arnold; Derk J Hogenkamp; Kelvin W Gee; James D Belluzzi; Frances M Leslie
Journal:  Neuropharmacology       Date:  2011-03-23       Impact factor: 5.250

5.  Effects of the neurotensin NTS₁ receptor agonist PD149163 on visual signal detection in rats.

Authors:  Todd M Hillhouse; Adam J Prus
Journal:  Eur J Pharmacol       Date:  2013-09-25       Impact factor: 4.432

Review 6.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

7.  Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats.

Authors:  Edward D Levin; Susan Slade; Michael Johnson; Ann Petro; Kofi Horton; Paul Williams; Amir H Rezvani; Jed E Rose
Journal:  Eur J Pharmacol       Date:  2008-10-17       Impact factor: 4.432

Review 8.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

9.  Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration.

Authors:  Nurith Amitai; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2008-07-11       Impact factor: 4.530

10.  Effects of chronic sazetidine-A, a selective α4β2 neuronal nicotinic acetylcholine receptors desensitizing agent on pharmacologically-induced impaired attention in rats.

Authors:  Amir H Rezvani; Marty Cauley; Yingxian Xiao; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2012-10-26       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.